Conferences - Results from #60

Viewing 61-80 of 11532 articles

SNMMI 2024: COBRA: Assessment of Safety and Efficacy of 64Cu-SAR-bisPSMA in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy

SNMMI 2024: Non-PSMA Targets for Prostate Cancer Radiopharmaceutical Therapies

SNMMI 2024: VIOLET: Radiation Absorbed Dose in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 161Tb-PSMA-I&T

SNMMI 2024: Dosimetry and Pilot Therapy Study of Novel PSMA-Targeting Agents, 177Lu-P17-087 and 177Lu-P17-088, in Metastatic Castration-Resistant Prostate Cancer Patients

SNMMI 2024: Preclinical and First-in-Human Studies of Dansylated Amino Acid Modified Long-Acting PSMA Derivative 68Ga/177Lu-LNC1011

SNMMI 2024: Combination Treatment of Prostate Cancer Using Pembrolizumab with PSMA Based Radioligands

AMA 2024: Championing Change: The AMA's Vital Advocacy Initiatives for Physicians

SNMMI 2024: Safety, Tolerability, and Dosimetry of TLX591 with Best Standard of Care in Patients with PSMA-Expressing Metastatic Castration Resistant Prostate Cancer: ProstACT SELECT Preliminary Results

SNMMI 2024: PSMA PET in Patients with Prostate Cancer – Gained Insights from Eight Years of Reimbursable Imaging

SNMMI 2024: Saul Hertz’s Theranostic Dream is Shaping the Future of Cancer Care: Bridging Evidence-Based Medicine and Precision Oncology

SNMMI 2024: PSMA Radioligand Therapy in Patients with Prostate Cancer: Technical Considerations for Diagnostic, Quantitative, and Dosimetric Imaging

SNMMI 2024: Novel Approaches of Combination PSMA-Based Radiopharmaceutical Treatments for Prostate Cancer

SNMMI 2024: Analysis of the Prospective ProsTIC Registry

SNMMI 2024: 225Ac-PSMA / 177Lu-PSMA Tandem Therapy for Metastatic Castration-Resistant Prostate Cancer – A Prospective Phase 3 Randomized Study from Azerbaijan

SNMMI 2024: Efficacy and Toxicity of 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer in a Real-World Setting: Results from the U.S. Expanded Access Program and Comparison with Phase 3 VISION Data

SNMMI 2024: Effect of Bone Marrow Disease on Hematologic Toxicity and PSA Response to 177Lu-PSMA-617 Therapy

SNMMI 2024: Lu-177-PSMA-I&T Treatment in Metastatic Castration Resistant Prostate Cancer: First Experience in Thailand

SNMMI 2024: PSMA RLT: Is Earlier Better?

SNMMI 2024: Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer (PSMAfore)

SNMMI 2024: Influence of Androgen Receptor Signaling Inhibitors on Absorbed Doses in mCRPC Patients Undergoing 177Lu-PSMA-617 Therapy: First Dosimetry Results

1
2
3
4
5
6
7
8
9
10